EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Targeting Melanoma Cell Adhesion Molecule as a Novel Therapeutic Approach for Acral Melanoma

Yuka Tanaka, Takamichi Ito iD, Kiichiro Nishio, Keiko Tanegashima, Takeshi Nakahara iD

Experimental Dermatology · 2025

DOI: 10.1111/exd.70164 ↗

At a glance

Journal article in Experimental Dermatology, 2025. Written by Yuka Tanaka and 4 co-authors. Institution: Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Major MEDLINE topics: Melanoma, Skin Neoplasms, CD146 Antigen. 79 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Japan Society for the Promotion of Science.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Acral melanoma (AM) is a rare subtype of cutaneous melanoma mainly found in acral locations. The treatment of advanced AM remains challenging due to its rarity and the distinct features of this subtype compared with the other common types of melanomas. There is thus an urgent need to develop effective therapeutic approaches for AM. This study was established to screen and evaluate potential therapeutic targets for AM. DNA microarray analysis comparing normal epidermal melanocytes and AM cell lines (SM2‐1 and MMG‐1) showed that approximately 500 genes were highly expressed in the AM cell lines compared with the levels in normal melanocytes. Among them, melanoma cell adhesion molecule (MCAM) was selected for further analyses and was found to be significantly highly expressed in AM cell lines compared with the levels in melanocytes and keratinocytes. Knockdown of MCAM significantly inhibited the proliferation of AM cell lines with decreased expression of cyclin D1 and BCL2. The cytotoxicity of MCAM‐targeted antibody‐drug conjugate was further evaluated and it significantly decreased the viability of AM cell lines. In conclusion, MCAM is highly expressed in AM cell lines and affects their proliferation, likely through modulating the expression of cyclin D1 and BCL2. These findings highlight the potential of MCAM as a therapeutic target of AM.

Subjects

MeSH terms (MEDLINE)

MelanomaSkin NeoplasmsCD146 AntigenHumansCell Line, TumorCell ProliferationCyclin D1MelanocytesProto-Oncogene Proteins c-bcl-2KeratinocytesGene Expression Regulation, NeoplasticCell Survival

Author keywords

DNA microarrayacral melanomaantibody‐drug conjugate (ADC)melanoma cell adhesion molecule (MCAM)targeted therapy

Substances

Cyclin D1CD146 AntigenMCAM protein, humanProto-Oncogene Proteins c-bcl-2CCND1 protein, humanBCL2 protein, human

Authors and institutions

  • Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

ORCID profiles: Takamichi Ito, Takeshi Nakahara

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Tanaka, Y., Ito, T., Nishio, K., Tanegashima, K., & Nakahara, T. (2025). Targeting Melanoma Cell Adhesion Molecule as a Novel Therapeutic Approach for Acral Melanoma. Experimental Dermatology. https://doi.org/10.1111/exd.70164

Vancouver

Tanaka Y, Ito T, Nishio K, Tanegashima K, Nakahara T. Targeting Melanoma Cell Adhesion Molecule as a Novel Therapeutic Approach for Acral Melanoma. Experimental Dermatology. 2025. doi:10.1111/exd.70164

BibTeX
@article{Tanaka2025,
  author = {Tanaka, Yuka and Ito, Takamichi and Nishio, Kiichiro and Tanegashima, Keiko and Nakahara, Takeshi},
  title = {Targeting Melanoma Cell Adhesion Molecule as a Novel Therapeutic Approach for Acral Melanoma},
  journal = {Experimental Dermatology},
  year = {2025},
  doi = {10.1111/exd.70164}
}
Start for free →